<!doctype html>
<html>
<head>
<meta charset="UTF-8">
<meta name="apple-mobile-web-app-capable" content="yes">
<meta name="viewport" content="width=device-width initial-scale=1, user-scalable=no">
<meta name="apple-mobile-web-app-title" content="AstraZeneca | LYNPARZA">
<title>AstraZeneca | LYNPARZA</title>
<link rel="stylesheet" type="text/css" href="css/animate.min.css" />
<link rel="stylesheet" type="text/css" href="css/swiper.min.css" />
<link rel="stylesheet" type="text/css" href="css/style.css" />
<style type="text/css">
	.intro, .swiper-scroll { float:left; }
	.intro { width:274px; height:395px; padding:25px 20px 20px; margin-right:22px; background-color:rgba(0, 77, 116, 0.15); }
	.intro i { display:block; margin-top:5px; font-size:14px; line-height:20px; }
	.swiper-container.swiper-scroll { width:608px; height:405px; }
	.swiper-scroll h4 { color:#b2d234; text-align:right; }
	.swiper-scroll h4, .swiper-scroll .tabular { font-size:11px; line-height:14px; }
	.swiper-scroll .tabular { margin-top:5px; }
	.swiper-scroll .tabular th { padding:5px; font-size:inherit; line-height:inherit; border-right:1px solid #ffffff; border-bottom:1px solid #ffffff; font-family:interstateregular; }
	.swiper-scroll .tabular tr:nth-child(2) th { padding:3px 5px 2px; }
	.tabular th:first-child { width:210px; }
	.swiper-scroll .tabular th:last-child { border-right:none; }
	.swiper-scroll .tabular td { padding: 6px 15px;}
	[data-slide='20'] > h2, [data-slide='21'] > h2 { margin-bottom:35px; }
	.footnote.abs { left:338px; bottom:108px; } 
	.btn-arrow i { font-family:interstateregular; color:#004d74; font-size:20px; line-height:20px; position:absolute; height:20px; left:55px; top:0; bottom:0; margin:auto 0; }
	.btn-arrow:before { content:"\e603"; font-size: 38px; position:absolute; left:12%; top:0; height:inherit; -webkit-transform:rotate(-90deg); transform:rotate(-90deg); }
	.btn-arrow.brcam { background-color:#b2d234; }
	.btn-arrow.brcam i { color:#b2d234; }
	.brcam .one, .two { display:none; }
	.brcam .two, .one { display:inline; }
	/* 21 */
	.dosing { font-family:interstatelightCon; height:395px;  position:relative; opacity:0; }
	.dosing:before, .dosing:after, .dosing > li:after, .btn.plus:before, .btn.plus:after { content:""; position:absolute; z-index:2; }
	.dosing:before, .dosing:after { width:82px; height:inherit; top:0; background-image:url(img/dosing.svg); background-repeat:no-repeat;  }
	.dosing:after { left:483px; background-position-y:-409px; }
	.dosing > li { float:left; width:131px; height:130px; background-color:#b2d234; color:#ffffff; position:relative;  top:165px; text-align:center; opacity:0; }
	.dosing > li:first-child { margin-left:95px; }
	.dosing > .parza { width:105px; height:140px; margin-top:-5px; color:#004d74; }
	.dosing > .parza, .dosing > .parza:after { background-color:#d9e4ea; }
	.dosing > li:nth-child(3) { margin-right:115px; }
	.dosing > li:after { width:20px; height:20px; right:-9px; top:0; bottom:0; margin:auto 0; -webkit-transform:rotate(45deg); transform:rotate(45deg); background-color:#b2d234; }
	.dosing > li:last-child:after { display:none; }
	.dosing > li i { display:table-cell; width:inherit; height:inherit; vertical-align:middle; }
	.dosing strong { font-family:interstatebold-condensed; }
	.popup-info { position:absolute; left:98px; bottom:70px; width:420px; height:65px; padding:48px 25px 18px; background-color:#004d74; color:#ffffff; z-index:5; display:none; }
	.popup-info .close { width:38px; height: 38px;right: 0px; top: 0px; background:none; }
	.popup-info .close:before { font-size:38px; }
	.btn.plus { width:23px; height:23px; bottom:auto; top:275px; left:28px; background:none; border:2px solid #80a6ba; border-radius:200px; opacity:0; -webkit-transform:scale(0); transform:scale(0); }
	.btn.plus.plus-2 { top:164px; left:85px; }
	.btn.plus.plus-3 { left:260px; }
	.btn.plus.plus-4 { left:860px; }
	.btn.plus:before, .btn.plus:after { left:0; right:0; top:0; bottom:0; margin:auto auto; background-color:#80a6ba; }
	.btn.plus:before { width:3px; height:14px; }
	.btn.plus:after { width:14px; height:3px; }
	.btn.plus.active { border-color: #4d829e; }
	.btn.plus.active:before, .btn.plus.active:after { background-color:#4d829e; }
	
	/* 21b */
	[data-slide='21b'] > h2 { margin-bottom:65px; letter-spacing:-0.015em; }
	.capsule { width:624px; height:420px; margin: 0 0 80px 250px; background-image:url(img/capsule.svg); background-repeat:no-repeat; position:relative; }
	.capsule li { position:absolute; left:0; top:155px; font-size:21px; line-height:24px; font-family:interstatebold-condensed; text-align:center; }
	.capsule li:nth-child(2) { top:95px; left:240px; }
	.capsule li:nth-child(3), .capsule li:nth-child(6) { left:auto; right:-2px; }
	.capsule li:nth-child(4),
	.capsule li:nth-child(6) { top:375px; }
	.capsule li:nth-child(5) { top:320px; left:264px; }
	.capsule li:nth-child(n+7) { top:40px; left:-200px; font-size:27px; line-height:30px; color:#b2d234; font-family:interstateregular-condensed; }
	.capsule li:last-child { top:265px; }
	
	.dosing, .dosing:before, .dosing:after, .capsule { background-size:100% auto; }
	.overlay .item.info { font-size:18px; line-height:23px; }
    	
	.tabular span, .dosing:before, .dosing:after { -webkit-transition:all 0.5s ease-in-out; transition:all 0.5s ease-in-out; }
	
</style> 
</head>
<body>
	<section id="container">
    	<nav class="nav-top icon">
            <ul>
                <li data-href="home"></li>
                <li data-href="warning">Contraindications<br />and Warnings</li>
                <li data-href="pi">PI</li>
                <li data-href="bibliography"></li>
                <li data-href="resource"></li>
                <li data-href="menu"></li>
            </ul>
        </nav>
    	<article class="content">
        	<!--subslides-->
            <div class="swiper-container swiper-parent">
                <ul class="swiper-wrapper">
                	<!-- slide 16-->
                    <li class="swiper-slide" data-slide="20">
                         <h2><span>SAFETY AND TOLERABILITY</span>
                         	THE SAFETY AND TOLERABILITY OF LYNPARZA ARE ACCEPTABLE<br />
FOR ORAL MAINTENANCE TREATMENT ADMINISTRATION<sup data-ref="4">4</sup>
                        </h2>
                        <div class="intro">
                        	<span class="one">More patients in the olaparib<br />
group than in the placebo<br />
group had dose interruptions<br />
(49 [36%] of 136 vs 21 [16%]<br />
of 128) or dose reductions 57<br />
[42%] vs 28 [22%]): vomiting,<br />
nausea, and fatigue were the<br />
most common causes of dose<br />
interruptions or reductions in the
olaparib group.<sup data-ref="3,4">3,4</sup>
<i>Serious adverse events were reported in<br />
25 (18%) of 136 patients in the olaparib<br />
group and 11 (9%) of 128 patients in<br />
the placebo group; the most common<br />
serious adverse event was small intestinal<br />
obstruction (two [1%] patients in the<br />
olaparib group and three [2%] in the<br />
placebo group.</i></span>
<span class="two">The most common adverse<br />
events associated with Lynparza<br />
monotherapy for patients<br />
identified with BRCAm were<br />
nausea, fatigue and vomiting and<br />
were generally mild to moderate<br />
(grade 1 or 2) in severity.<br />
The most common Grade 3<br />
and 4 adverse events reported<br />
for Lynparza vs placebo were<br />
fatigue (7% vs 2%) and anaemia<br />
(5% vs 2%), neutropenia (4% vs<br />
2%) and vomiting (3% vs 0%)<sup data-ref="3,4">3,4</sup></span>
                        </div>
                         <!-- Swiper scroll -->
                        <div class="swiper-container swiper-scroll">
                            <div class="swiper-wrapper">
                              <div class="swiper-slide">
                               	<h4><i class="one">OVERALL PATIENT POPULATION</i><i class="two">PATIENTS WITH BRCA MUTATION</i></h4>
                                   <table width="100%" border="0" cellspacing="0" cellpadding="0" class="tabular">
                                     <tbody>
                                       <tr>
                                         <th></th>
                                         <th colspan="2">All grades</th>
                                         <th colspan="2">Grade <span class="sym">â‰¥</span>3</th>
                                       </tr>
                                       <tr>
                                         <th></th>
                                         <th>Olaparib<br />(n=<i class="one">136</i><i class="two">74</i>)</th>
                                         <th>Placebo<br />(n=<i class="one">128</i><i class="two">62</i>)</th>
                                         <th>Olaparib<br />(n=<i class="one">136</i><i class="two">74</i>)</th>
                                         <th>Placebo<br />(n=<i class="one">128</i><i class="two">62</i>)</th>
                                       </tr>
                                       <tr>
                                         <td>Patients with any AE</td>
                                         <td><i class="one">132</i><i class="two">72</i> (97%)</td>
                                         <td><i class="one">119 (93%)</i><i class="two">58 (94%)</i></td>
                                         <td><i class="one">55 (40%)</i><i class="two">28 (38%)</i></td>
                                         <td><i class="one">28 (22%)</i><i class="two">11 (18%)</i></td>
                                       </tr>
                                       <tr class="white">
                                         <td>Nausea</td>
                                         <td><i class="one">96 (71%)</i><i class="two">54 (73%)</i></td>
                                         <td><i class="one">46 (36%)</i><i class="two">20 (32%)</i></td>
                                         <td><i class="one">3 (2%)</i><i class="two">1 (1%)</i></td>
                                         <td>0</td>  
                                       </tr>
                                       <tr>
                                         <td>Fatigue</td>
                                         <td><i class="one">71 (52%)</i><i class="two">40 (54%)</i></td>
                                         <td><i class="one">50 (39%)</i><i class="two">23 (37%)</i></td>
                                         <td><i class="one">10 (7%)*</i><i class="two">5 (7%)</i></td>
                                         <td><i class="one">4 (3%)</i><i class="two">1 (2%)</i></td>
                                       </tr>   
                                       <tr class="white">
                                         <td>Vomiting</td>
                                         <td><i class="one">46 (34%)</i><i class="two">27 (36%)</i></td>
                                         <td><i class="one">18 (14%)</i><i class="two">5 (8%)</i></td>
                                         <td><i class="one">3 (2%)</i><i class="two">2 (3%)</i></td>
                                         <td><i class="one">1 (&lt;1%)</i><i class="two">0</i></td>
                                       </tr> 
                                       <tr>
                                         <td>Diarrhoea</td>
                                        <td><i class="one">37 (27%)</i><i class="two">22 (30%)</i></td>
                                         <td><i class="one">31 (24%)</i><i class="two">12 (19%)</i></td>
                                         <td><i class="one">3 (2%)</i><i class="two">2 (3%)</i></td>
                                         <td><i class="one">3 (2%)</i><i class="two">1 (2%)</i></td>
                                       </tr>  
                                       <tr class="white">
                                         <td>Abdominal pain</td>
                                         <td><i class="one">34 (25%)</i><i class="two">17 (23%)</i></td>
                                         <td><i class="one">34 (27%)</i><i class="two">18 (29%)</i></td>
                                         <td><i class="one">3 (2%)</i><i class="two">0</i></td>
                                         <td><i class="one">4 (3%)*</i><i class="two">2 (3%)</i></td>
                                       </tr> 
                                       <tr>
                                         <td>Anaemia</td>
                                        <td><i class="one">29 (21%)</i><i class="two">19 (26%)</i></td>
                                         <td><i class="one">7 (5%)</i><i class="two">3 (5%)</i></td>
                                         <td><i class="one">7 (5%)*</i><i class="two">4 (5%)</i></td>
                                         <td><i class="one">1 (&lt;1%)</i><i class="two">1 (2%)</i></td>
                                       </tr>  
                                       <tr class="white">
                                         <td>Headache</td>
                                         <td><i class="one">28 (21%)</i><i class="two">13 (18%)</i></td>
                                         <td><i class="one">16 (13%)</i><i class="two">10 (16%)</i></td>
                                         <td>0</td>
                                         <td><i class="one">1 (&lt;1%)</i><i class="two">1 (2%)</i></td>
                                       </tr>
                                       <tr>
                                         <td>Constipation</td>
                                        <td><i class="one">28 (21%)</i><i class="two">14 (19%)</i></td>
                                         <td><i class="one">14 (11%)</i><i class="two">7 (11%)</i></td>
                                         <td>0</td>
                                         <td>0</td>
                                       </tr> 
                                       <tr class="white">
                                         <td>Decreased appetite</td>
                                         <td><i class="one">28 (21%)</i><i class="two">14 (19%)</i></td>
                                         <td><i class="one">17 (13%)</i><i class="two">6 (10%)</i></td>
                                         <td>0</td>
                                         <td>0</td>
                                       </tr> 
                                       <tr>
                                         <td>Dyspepsia</td>
                                        <td><i class="one">24 (18%)</i><i class="two">13 (18%)</i></td>
                                         <td><i class="one">11 (9%)</i><i class="two">4 (6%)</i></td>
                                         <td>0</td>
                                         <td>0</td>
                                       </tr> 
                                       <tr class="white">
                                         <td>Cough</td>
                                         <td><i class="one">24 (18%)</i><i class="two">11 (15%)</i></td>
                                         <td><i class="one">13 (10%)</i><i class="two">7 (11%)</i></td>
                                         <td>0</td>
                                         <td>0</td>
                                       </tr> 
                                       <tr>
                                         <td>Upper abdominal pain </td>
                                        <td><i class="one">24 (18%)</i><i class="two">14 (19%)</i></td>
                                         <td><i class="one">10 (8%)</i><i class="two">4 (6%)</i></td>
                                         <td>0</td>
                                         <td><i class="one">1 (&lt;1%)</i><i class="two">0</i></td>
                                       </tr> 
                                       <tr class="white">
                                         <td>Arthralgia</td>
                                         <td><i class="one">23 (17%)</i><i class="two">11 (15%)</i></td>
                                         <td><i class="one">18 (14%)</i><i class="two">10 (16%)</i></td>
                                         <td><i class="one">1 (&lt;1%)</i><i class="two">1 (1%)</i></td>
                                         <td>0</td>
                                       </tr>
                                       <tr>
                                         <td>Back pain</td>
                                         <td><i class="one">22 (16%)</i><i class="two">14 (19%)</i></td>
                                         <td><i class="one">14 (11%)</i><i class="two">9 (15%)</i></td>
                                         <td><i class="one">3 (2%)</i><i class="two">2 (3%)</i></td>
                                         <td>0</td>
                                       </tr>  
                                       <tr class="white">
                                         <td>Dysgeusia</td>
                                         <td><i class="one">22 (16%)</i><i class="two">14 (19%)</i></td>
                                         <td><i class="one">8 (6%)</i><i class="two">4 (6%)</i></td>
                                         <td>0</td>
                                         <td>0</td>
                                       </tr> 
                                        <tr>
                                         <td>Nasopharyngitis</td>
                                         <td><i class="one">20 (15%)</i><i class="two">10 (14%)</i></td>
                                         <td><i class="one">14 (11%)</i><i class="two">4 (6%)</i></td>
                                         <td>0</td>
                                         <td>0</td>
                                       </tr>
                                       <tr class="white">
                                         <td>Asthenia</td>
                                         <td><i class="one">19 (14%)</i><i class="two">12 (16%)</i></td>
                                         <td><i class="one">12 (9%)</i><i class="two">8 (13%)</i></td>
                                         <td><i class="one">1 (&lt;1%)</i><i class="two">1 (1%)</i></td>
                                         <td>0</td>
                                       </tr>  
                                        <tr>
                                         <td>Dizziness</td>
                                         <td><i class="one">18 (13%)</i><i class="two">11 (15%)</i></td>
                                         <td><i class="one">9 (7%)</i><i class="two">3 (5%)</i></td>
                                         <td>0</td>
                                         <td>0</td>
                                       </tr> 
                                       <tr class="white">
                                         <td>Abdominal distension</td>
                                         <td><i class="one">17 (13%)</i><i class="two">9 (12%)</i></td>
                                         <td><i class="one">11 (9%)</i><i class="two">6 (10%)</i></td>
                                         <td>0</td>
                                         <td>0</td>
                                       </tr> 
                                       <tr>
                                         <td>Neutropenia</td>
                                         <td><i class="one">7 (5%)</i><i class="two">5 (7%)</i></td>
                                         <td><i class="one">5 (4%)</i><i class="two">3 (5%)</i></td>
                                         <td><i class="one">5 (4%)<sup>â€ </sup></i><i class="two">3 (4%)*</i></td>
                                         <td><i class="one">1 (&lt;1%)</i><i class="two">1 (2%)</i></td>
                                       </tr>   
                                     </tbody>
                                  </table>
                                    
                                </div>
                            </div>
                            <!-- Scroll Bar -->
                            <div class="swiper-scrollbar"></div>
                        </div>
                        <span class="footnote slim abs"><i class="one"><sup>â€ </sup>Includes three patients</i><i class="two">*Includes one patient</i> with a grade 4 AE.<br />
Adapted with permission from Ledermann.<sup data-ref="3">3</sup></span>
            		</li>
                    <!-- slide 21 -->
                    <li class="swiper-slide" data-slide="21">
                         <h2><span>DOSING</span>
                         	LYNPARZA IS THE ONLY ORAL TGA APPROVED MAINTENANCE<br />
THERAPY FOR BRCAm PLATINUM-SENSITIVE RELAPSED HIGH<br />
GRADE SEROUS OVARIAN CANCER PATIENTS<sup data-ref="4">4</sup>
                        </h2>
                        <ul class="dosing">
                        	<li>
                            	<i>Wait to take <br />Lynparza at <br />least <strong>1 hour</strong> after&nbsp;food</i>
                            </li>
                        	<li class="parza"><i><strong>Lynparza<br />400 mg</strong></i></li>
                        	<li><i>Refrain from<br />
eating preferably<br />
for up to<br />
<strong>2 hours</strong> after<br />
taking Lynparza</i></li>
                        	<li>
                            <i>Wait to take<br />
Lynparza at<br />
least <strong>1 hour</strong><br />
after food</i>
                            </li>
                        	<li class="parza"><i><strong>Lynparza<br />400 mg</strong></i></li>
                        	<li>
                            	<i>Refrain from<br />
eating preferably<br />
for up to<br />
<strong>2 hours</strong> after<br />
taking Lynparza</i>
                            </li>
                        </ul>
                        
                        <span class="btn plus plus-1"></span>
                        <span class="btn plus plus-2"></span>
                        <span class="btn plus plus-3"></span>
                        <span class="btn plus plus-4"></span>
                        <div class="popup-info"><span class="icon close"></span>
                        	<span data-info="1">
                            	Due to the effect of food on Lynparza absorption,<br />
                                Lynparza should be taken at the same time relative<br />
                                to time of eating, and preferably after food intake<sup data-ref="4">4</sup>
							</span>
                        	<span data-info="2" class="hide">
                            	Patients should start treatment with Lynparza no<br />
                                later than 8 weeks after completion of their final<br />
                                dose of the platinum-containing regimen<sup data-ref="4">4</sup>
							</span>
                            <span data-info="3" class="hide">
                            	The recommended dose of Lynparza is 400mg<br />
                                (eight 50mg capsules) taken twice daily, equivalent<br />
                                to a total daily dose of 800 mg<sup data-ref="4">4</sup>
							</span>
                            <span data-info="4" class="hide">
                            	It is recommended that treatment be continued<br />
                                until disease progression of the underlying disease<sup data-ref="4">4</sup>
							</span>
                        	
                        </div>
            		</li>
                    <!-- slide 21 -->
                    <li class="swiper-slide" data-slide="21b">
                         <h2><span>DOSING</span>
                         	DOSE ADJUSTMENTS MAY BE REQUIRED TO MANAGE ADVERSE EVENTS
SUCH AS NAUSEA, VOMITING, DIARRHOEA, AND ANAEMIA<sup data-ref="4">4</sup>
                        </h2>
                        <ul class="capsule">
                        	<li>400 mg twice daily</li>
                            <li>RECOMMENDED<br />REDUCTION</li>
                        	<li>200 mg twice daily</li>
                        	<li>200 mg twice daily</li>
                            <li>FINAL<br />REDUCTION</li>
                        	<li>100 mg twice daily</li>
                        	
                        	<li>If dose reduction<br />is necessary:</li>
                        	<li>If further dose<br />reduction is<br />necessary:</li>
                        </ul>
                        <div class="footnote slim">Adapted from Lynparza (olaparib) Approved Product lnformation.<sup data-ref="4">4</sup></div>
                    </li>
            	</ul><!-- end swiper-wrapper -->
                <!-- Add Arrows -->
       			<span class="swiper-button icon arrow swiper-button-next"></span>
        		<span class="swiper-button icon arrow swiper-button-prev"></span>
        	</div>
        	<span class="logo lynp"></span>
            <span class="btn icon btn-arrow brcam"><i>BRCAm</i></span>
            <span class="btn btn-info hide">i</span>
        </article>
    
    <!-- popup -->
    <div class="overlay shade ">
    	<!-- reference -->
    	<div class="ref hide">
            <div class="item"> <span class="close icon"></span>
                <h1>References</h1>
                <ol></ol>
            </div>
        </div><!-- end ref -->
         <!-- info -->
        <div class="item info " data-info="18"><span class="arrow icon"></span>
        <ul class="list">
        	<li>The recommended dose of Lynparza is 400mg (eight 50mg capsules) taken twice daily, equivalent to a total<br />daily dose of 800 mg<sup data-ref="4">4</sup></li>
<li>Patients should start treatment with Lynparza no later than 8 weeks after completion of their final dose<br />
of the platinum-containing regimen<sup data-ref="4">4</sup></li>
<li>Due to the effect of food on Lynparza absorption, patients should take Lynparza should be take<br />
at the same time relative to time of eating, and preferably after food intake<sup data-ref="4">4</sup></li>
<li>It is recommended that treatment be continued until disease progression of the underlying disease<sup data-ref="4">4</sup></li>
<li>Baseline testing, followed by monthly monitoring, of complete blood counts is recommended for the first<br />
12 months of treatment and periodically after this time to monitor for clinically significant changes in any<br />
parameter during treatment<sup data-ref="4">4</sup></li>
        </ul>
           
        </div><!-- end info -->
       <!-- navigation -->
        <div class="item nav hide"><span class="close icon"></span>
        	<ul class="section">
        		<li data-href="1"><span>Unmet need</span></li>
        		<li data-href="2"><span>Mechanism<br />of action</span>
                	<ul>
                		<li data-href="2"><span>PARPi</span></li>
                		<li data-href="3"><span>DNA repair</span></li>
                	</ul>
                </li>
        		<li data-href="4"><span>Clinical Data</span>
                	<ul>
                		<li data-href="4"><span>Extended PFS</span></li>
                		<li data-href="5"><span>Study overview</span></li>
                		<li data-href="6"><span>BRCAm<br />sub-analysis</span></li>
                		<li data-href="7"><span>TFST<br />Exploratory Analysis</span></li>
                		<li data-href="8"><span>TSST<br />Exploratory Analysis</span></li>
                		<li data-href="9"><span>Overall Survival</span></li>
                		<li data-href="10"><span><em>Post-Hoc</em> interim exploratory analysis of os</span></li>
                		<li data-href="11"><span>Patient Characteristics</span></li>
                	</ul>
                </li>
        		<li data-href="12"><span>BRCAm+</span>
                	<ul>
                		<li data-href="12"><span>BRCAm testing</span></li>
                		<li data-href="13"><span>About BRCAm</span></li>
                		<li data-href="14"><span>Testing<br />guidelines</span></li>
                		<li data-href="15"><span>BRCAm status</span></li>
                	</ul>
                </li>
        		<li data-href="16"><span>Patient<br />Support</span>
                	<ul>
                		<li data-href="16"><span>LYNPARZA Patient&nbsp;Access Programme</span></li>
                		<li data-href="17"><span>Patient&nbsp;Support Programme</span></li>
                		<li data-href="18"><span>Patient<br />Support Kit</span></li>
                		<li data-href="19"><span>Capsule<br />companion</span></li>
                	</ul>
                </li>
        		<li data-href="20"><span>Dosing &amp;<br />administration</span>
                	<ul>
                		<li data-href="20"><span>Safety and<br />tolerability</span></li>
                		<li data-href="21"><span>Dosing</span></li>
                	</ul>
                </li>
        		<li data-href="22"><span>Summary</span></li>
        	</ul>
            
        </div><!-- end nav -->
    </div>

    </section>
<script type="text/javascript" src="js/jquery-1.11.0.min.js"></script>
<script type="text/javascript" src="js/TweenMax.min.js"></script>
<script type="text/javascript" src="js/TimelineLite.min.js"></script>
<script type="text/javascript" src="js/swiper.min.js"></script>
<script type="text/javascript" src="js/touchy.js"></script>
<script type="text/javascript" src="js/script.js"></script>
<script type="text/javascript">
	$( function(){
		var tl2 = new TimelineLite(),
			tl3 = new TimelineLite(),
			label = ["BRCAm", "OPP"],
			container = $("#container"),
			btnArrow = $('.btn-arrow'),
			info = $('.btn-info'),
			dosing = $('.dosing'),
			plus = $('.btn.plus'),
			popupInfo = $('.popup-info'),
			txtArrow = $('.btn-arrow i');
		 var mySwiper = new Swiper('.swiper-parent', {
        	paginationClickable: true,
        	direction: 'vertical',
			nextButton: '.swiper-button-next',
        	prevButton: '.swiper-button-prev',
			onSlideChangeStart: function(e){
				console.log(e.activeIndex);
				//e.slideTo(9); 
				tl.pause(0);
				tl2.pause(0);
				tl3.pause(0);
				btnArrow.hide();
				info.hide();
				popupInfo.hide();
				switch(e.activeIndex){
					case 0:
						btnArrow.show();
					break;
					case 1:
						tl.play();
						info.show();
					break;
					case 2:
					break;
					case 3:
					break;
				}
			} 
		  });
		  
		var swiperScroll = new Swiper('.swiper-scroll', {
			scrollbar: '.swiper-scrollbar',
			direction: 'vertical',
			slidesPerView: 'auto',
			nested: true,
			mousewheelControl: true,
			freeMode: true,
			scrollbarDraggable: true,
			scrollbarHide: false
		});
		
		btnArrow.on('tap', function(){
			var t  = $(this);
				t.toggleClass('brcam');
				container.toggleClass('brcam');
				t.hasClass('brcam') ? txtArrow.text('BRCAm') : txtArrow.text('OPP');
		})
		tl.to(dosing, 0.5, { opacity:1, ease: Power0.easeOut, delay:0.25} )
			.staggerTo(dosing.find('li'), 0.3, { opacity:1, ease: Power0.easeOut }, 0.15, 'lab')
			.from(plus, 0.8, { top: 275, left: 28, ease: Power0.easeOut, delay:0.5}, 'lab' )
			.to(plus, 0.8, { opacity:1, scale:1, rotation: 360,  ease: Bounce.easeOut }, 'lab' );
		
		plus.on('tap', function(){
			var cl = $(this).attr('class').split(' ')[2].split('-')[1];
				popupInfo.find('span[data-info]').hide();
				
			if(!popupInfo.is(':visible')){ popupInfo.fadeIn(); }
				popupInfo.find('span[data-info='+cl+']').fadeIn();
		});
		popupInfo.on('tap', '.close', function(){
			$(this).parent().fadeOut();
		})
		//mySwiper.slideTo(1);
		/* $('.indicator .arrow').on('tap', function(){ 
				$(this).toggleClass('less').prev('p').slideToggle();
		 })*/
		
	})
</script>
</body>
</html>
